Table 1 Study characteristics and demographic data
Study | Year | Study Design | LOE | Mean MINORS Score | Mean FU, mo | Patients/Shoulders, n | Mean Age, yr | Male/Female, n |
|---|---|---|---|---|---|---|---|---|
Armbuster et al. [22] | 1977 | Case series | IV | 6 | NR | 5/5 | 63.4 | 5/0 |
Master et al. [12] | 1977 | Case series | IV | 5 | NR | 7/8 | 63 | 7/0 |
Gelberman et al. [1] | 1980 | Case series | IV | 7 | > 6 | 15/16 | 58 | NR |
Leslie et al. [6] | 1989 | Case series | IV | 8 | 31.2 | 18/18 | 63 | 14/4 |
Pfeiffenberg et al. [23] | 1996 | Case series | IV | 9 | NR | 14/14 | 57 | NR |
Lossos et al. [5] | 1998 | Case series | IV | 9 | NR | 6/6 | 76 | 4/2 |
Wick et al. [24] | 2003 | Case series | IV | 9 | NR | 11/11 | 52.1 | NR |
Chanet et al. [25] | 2005 | Case series | IV | 8 | NR | 6/6 | 67.6 | 0/6 |
Smith et al. [9] | 2005 | Case series | IV | 7 | 54 | 17/20 | 64 | 11/6 |
Jeon et al. [2] | 2006 | Case series | IV | 9 | 16.4 | 19/19 | 59 (23–89) | 17/2 |
Duncan et al. [8] | 2008 | Case series | IV | 10 | 6 | 19/19 | 75.5 (49–94) | NR |
Rhee et al. [26] | 2008 | Case series | IV | 9 | 30 | 13/13 | 56 | 10/3 |
Kirchhoff et al. [10] | 2008 | Case series | IV | 12 | NR | 25/25 | 66.5 | 15/10 |
Klinger et al. [3] | 2010 | Case series | IV | 11 | 35.4 | 21/23 | 64.7 | 10/11 |
Matsuhashi et al. [27] | 2011 | Case series | IV | 9 | 103.3 | 10/10 | 61.7 | 4/6 |
Abdel et al. [28] | 2013 | Case series | IV | 10 | 31 | 46/50 | 66 | 35/11 |
Garofalo et al. [29] | 2014 | Case series | IV | 8 | NR | 10/10 | 67.9 | 8/2 |
Cho et al. [30] | 2016 | Case series | IV | 12 | 32.4 | 32/34 | 61.8 | 15/17 |
Jung et al. [31] | 2016 | Case series | IV | 12 | 14 | 68/68 | 66.4 | 39/29 |
Sobreira et al. [32] | 2016 | Case series | IV | 7 | 12.2 | 7/8 | 74 | 4/3 |
Böhler et al. [33] | 2017 | Retrospective cohort | III | 20 | NR | 59/59 | 72 | 25/34 |
Jiang et al. [17] | 2017 | Retrospective cohort | III | 16 | NR | Group 1: 1223/1223 Group 2: 4355/4355 Group 3: 799/799 | Group1; 62.8 Group 2: 60.6 Group3: 62 | Group 1:682/541 Group 2: 2661/1694 Group 3: 490/309 |
Kim et al. [34] | 2018 | Retrospective cohort | III | 21 | Group s: 32.9 Group r: 30.8 | Group s: 29/29 Group r:13/13 | Group s: 61 Group r: 67.5 | Group s:14/15 Group r:7/6 |
Sweet et al. [35] | 2018 | Case series | IV | 11 | 83.1 | 97/97 | 58.2 | 58/39 |
Gramlich et al. [16] | 2019 | Case series | IV | 10 | NR | 29/29 | 73 (38–93) | 19/10 |
Lee et al. [13] | 2019 | Retrospective cohort | III | 18 | Group 1: 28.8 Group 2: 28.8 | Group 1: 27/27 Group 2: 30/30 | Group 1: 54.9 Group 2: 56.3 | Group 1: 12/15 Group 2: 19/11 |
Joo et al. [18] | 2020 | Retrospective case-control | III | 20 | NR | 97/97 | 61 | 53/44 |
Khazi et al. [19] | 2020 | Retrospective cohort | III | 16 | 1 | 204/204 | NR | 133/71 |
Kwon et al. [36] | 2020 | Case series | IV | 10 | 14.3 | 35/36 | 63.8 | 15/20 |
Rhee et al. [14] | 2020 | Case series | IV | 14 | 27.6 | 31/31 | 54.9 | 11/20 |
Takahasi et al. [37] | 2020 | Case series | IV | 11 | NR | 22/22 | 67.9 | 10/12 |